Myelodysplastic Syndromes: Iron Overload Consequences and Current Chelating Therapies

Publisher： Cambridge Scholars Publishing in association with GSE Research

ISSN： 1540-1405

Source： Journal of the National Comprehensive Cancer Network (JNCCN), Vol.4, Iss.1, 2006-01, pp. : 91-96

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Optimizing Therapy for Iron Overload in the Myelodysplastic Syndromes: Recent Developments

By Leitch Heather A.

Drugs, Vol. 71, Iss. 2, 2011-01 ,pp. : 155-177

Adis International

Access to resources Recommend Favorite

New chelation therapies and emerging chelating drugs for the treatment of iron overload

By Kontoghiorghes George J

Expert Opinion on Emerging Drugs, Vol. 11, Iss. 1, 2006-03 ,pp. : 1-5

Informa Healthcare

Access to resources Recommend Favorite

Pharmacoeconomic Considerations in Treating Iron Overload in Patients with β-Thalassaemia, Sickle Cell Disease and Myelodysplastic Syndromes in the US: A Literature Review

By Zhang Bin

PharmacoEconomics, Vol. 29, Iss. 6, 2011-06 ,pp. : 461-474

Adis International

Access to resources Recommend Favorite

Use chelation therapy to reduce iron overload and improve survival in patients with myelodysplastic syndromes

Drugs & Therapy Perspectives, Vol. 27, Iss. 9, 2011-09 ,pp. : 14-17

Adis International

Access to resources Recommend Favorite

Chelating Agents for the Treatment of Systemic Iron Overload

Current Medicinal Chemistry, Vol. 19, Iss. 17, 2012-06 ,pp. : 2816-2827

Bentham Science Publishers

Access to resources Recommend Favorite